Trial Profile

A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bomedemstat (Primary)
Indications Essential thrombocythaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Imago BioSciences

Most Recent Events

05 Jan 2024 According to Merck media release, data from the study were presented at the American Society for Hematology (ASH) Annual Meeting in December 2023.
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
28 Mar 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com